# Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)

> **NCT01534351** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Finasteride
- **DRUG:** Tamsulosin
- **DRUG:** Finasteride-matching placebo
- **DRUG:** Tamsulosin-matching placebo

## Key facts

- **NCT ID:** NCT01534351
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08-01
- **Primary completion:** 2013-11-18
- **Final completion:** 2013-11-18
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01534351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01534351, "Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01534351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*